Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200 mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment follow-up period, in patients with chronic Hepatitis D Virusinfection.
Objectives: To evaluate the safety and tolerability of once daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
To evaluate the effect of once daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period with a 24-week post-treatment follow-up on HDV viral levels.
Trial population: Up to 30 patients with chronic HDV infection with detectable HDV RNA and compensated liver disease.

开始日期2021-05-15

申办/合作机构

Soroka University Medical Center

[+1]

NCT03719313 / Completed临床3期

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)

Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and alanine aminotransferase (ALT) normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline.

开始日期2018-12-01

申办/合作机构

Eiger BioPharmaceuticals, Inc.

NCT03600714 / Completed临床2期IIT

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Background:
Infection with hepatitis D virus leads to a chronic liver disease with no effective treatment. Lonafarnib has improved hepatitis D virus levels in blood, but the medication still needs more research. Ritonavir makes other drugs more effective and is used with lonafarnib to make it more effective. Lambda interferon stimulates the body s response to viruses. Researchers want to see if combining these drugs fights hepatitis D and helps the liver.
Objectives:
To see if combining lonafarnib, ritonavir, and lambda interferon is safe and effective to treat chronic hepatitis D infection.
Eligibility:
Adults at least 18 years old with chronic hepatitis D infection
Design:
Participants will be screened with a physical exam, medical history, and blood and urine tests.
Throughout the study, all participants will:
Follow rules for medicine, food, and contraception
Take hepatitis B medicine
Have weight checked
Have routine blood and urine tests
Give stool samples
Female participants will have pregnancy tests.
Participants will have 3 visits before treatment. They will repeat screening tests and have a heart test and liver scan.
Participants will have a 5-day inpatient stay. They will:
Baseline blood and urine tests
Have eye tests
Answer health questions
Have a liver sample taken and liver blood pressure measured. Participants will be sedated.
Have reproductive tests
Start the study drugs and have blood draws
Over 24 weeks of treatment, participants will:
-Take 2 study drugs by mouth every day and 1 as a weekly injection

开始日期2018-08-01

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

100 项与洛那法尼相关的临床结果

登录后查看更多信息

100 项与洛那法尼相关的转化医学

登录后查看更多信息

100 项与洛那法尼相关的专利（医药）

登录后查看更多信息

282

项与洛那法尼相关的文献（医药）

2024-02-08·Nature communications

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.

Review

作者: Svenja M Sake ; Xiaoyu Zhang ; Manoj Kumar Rajak ; Melanie Urbanek-Quaing ; Arnaud Carpentier ; Antonia P Gunesch ; Christina Grethe ; Alina Matthaei ; Jessica Rückert ; Marie Galloux ; Thibaut Larcher ; Ronan Le Goffic ; Fortune Hontonnou ; Arnab K Chatterjee ; Kristen Johnson ; Kaycie Morwood ; Katharina Rox ; Walid A M Elgaher ; Jiabin Huang ; Martin Wetzke ; Gesine Hansen ; Nicole Fischer ; Jean-Francois Eléouët ; Marie-Anne Rameix-Welti ; Anna K H Hirsch ; Elisabeth Herold ; Martin Empting ; Chris Lauber ; Thomas F Schulz ; Thomas Krey ; Sibylle Haid ; Thomas Pietschmann

Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC₅₀: 10-118 nM). Passaging of RSV with lonafarnib selects for phenotypic resistance and fixation of mutations in the RSV fusion protein (T335I and T400A). Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mutations confer lonafarnib resistance. Surface plasmon resonance reveals RSV fusion protein binding of lonafarnib and co-crystallography identifies the lonafarnib binding site within RSV F. Oral administration of lonafarnib dose-dependently reduces RSV virus load in a murine infection model using female mice. Collectively, this work provides an overview of RSV drug repurposing candidates and establishes lonafarnib as a bona fide fusion protein inhibitor.

2023-12-01·Nucleus (Austin, Tex.)

The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.

Article

作者: Kamsi O Odinammadu ; Khurts Shilagardi ; Kelsey Tuminelli ; Daniel P Judge ; Leslie B Gordon ; Susan Michaelis

Several related progeroid disorders are caused by defective post-translational processing of prelamin A, the precursor of the nuclear scaffold protein lamin A, encoded by LMNA. Prelamin A undergoes farnesylation and additional modifications at its C-terminus. Subsequently, the farnesylated C-terminal segment is cleaved off by the zinc metalloprotease ZMPSTE24. The premature aging disorder Hutchinson Gilford progeria syndrome (HGPS) and a related progeroid disease, mandibuloacral dysplasia (MAD-B), are caused by mutations in LMNA and ZMPSTE24, respectively, that result in failure to process the lamin A precursor and accumulate permanently farnesylated forms of prelamin A. The farnesyl transferase inhibitor (FTI) lonafarnib is known to correct the aberrant nuclear morphology of HGPS patient cells and improves lifespan in children with HGPS. Importantly, and in contrast to a previous report, we show here that FTI treatment also improves the aberrant nuclear phenotypes in MAD-B patient cells with mutations in ZMPSTE24 (P248L or L425P). As expected, lonafarnib does not correct nuclear defects for cells with lamin A processing-proficient mutations. We also examine prelamin A processing in fibroblasts from two individuals with a prevalent laminopathy mutation LMNA-R644C. Despite the proximity of residue R644 to the prelamin A cleavage site, neither R644C patient cell line shows a prelamin A processing defect, and both have normal nuclear morphology. This work clarifies the prelamin A processing status and role of FTIs in a variety of laminopathy patient cells and supports the FDA-approved indication for the FTI Zokinvy for patients with processing-deficient progeroid laminopathies, but not for patients with processing-proficient laminopathies.

2023-11-09·JAMA

Hepatitis D: A Review.

Review

作者: Francesco Negro ; Anna S Lok

Importance:

Hepatitis D virus (HDV) infection occurs in association with hepatitis B virus (HBV) infection and affects approximately 12 million to 72 million people worldwide. HDV causes more rapid progression to cirrhosis and higher rates of hepatocellular carcinoma than HBV alone or hepatitis C virus.

Observations:

HDV requires HBV to enter hepatocytes and to assemble and secrete new virions. Acute HDV-HBV coinfection is followed by clearance of both viruses in approximately 95% of people, whereas HDV superinfection in an HBV-infected person results in chronic HDV-HBV infection in more than 90% of infected patients. Chronic hepatitis D causes more rapidly progressive liver disease than HBV alone. Approximately 30% to 70% of patients with chronic hepatitis D have cirrhosis at diagnosis and more than 50% die of liver disease within 10 years of diagnosis. However, recent studies suggested that progression is variable and that more than 50% of people may have an indolent course. Only approximately 20% to 50% of people infected by hepatitis D have been diagnosed due to lack of awareness and limited access to reliable diagnostic tests for the HDV antibody and HDV RNA. The HBV vaccine prevents HDV infection by preventing HBV infection, but no vaccines are available to protect those with established HBV infection against HDV. Interferon alfa inhibits HDV replication and reduces the incidence of liver-related events such as liver decompensation, hepatocellular carcinoma, liver transplant, or mortality from 8.5% per year to 3.3% per year. Adverse effects from interferon alfa such as fatigue, depression, and bone marrow suppression are common. HBV nucleos(t)ide analogues, such as entecavir or tenofovir, are ineffective against HDV. Phase 3 randomized clinical trials of bulevirtide, which blocks entry of HDV into hepatocytes, and lonafarnib, which interferes with HDV assembly, showed that compared with placebo or observation, these therapies attained virological and biochemical response in up to 56% of patients after 96 weeks of bulevirtide monotherapy and 19% after 48 weeks of lonafarnib, ritonavir, and pegylated interferon alfa treatment.

Conclusions and Relevance:

HDV infection affects approximately 12 million to 72 million people worldwide and is associated with more rapid progression to cirrhosis and liver failure and higher rates of hepatocellular carcinoma than infection with HBV alone. Bulevirtide was recently approved for HDV in Europe, whereas pegylated interferon alfa is the only treatment available in most countries.

项与洛那法尼相关的新闻（医药）

2024-04-02

·BioSpace

Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year

Pictured: A U.S. federal bankruptcy courthouse building/iStock, GussWilder Eiger BioPharmaceuticals on Monday announced that it has voluntarily filed for bankruptcy and has kicked off the process of selling its assets and winding down the company’s operations. The California-based biotech has filed for Chapter 11 protection with the Bankruptcy Court for the Northern District of Texas, and has also submitted customary “first day” motions. If granted, the motion will provide Eiger some relief allowing it to transition into bankruptcy while it meets the company’s commitments to its stakeholders without “material disruptions” to its ordinary operations, according to the announcement. Eiger will sell all its assets during the bankruptcy case as it prepares for “an orderly wind down” of its operations. As part of the process, the biotech has inked a “stalking horse” agreement with rare disease player Sentynl Therapeutics which has agreed to purchase Zokinvy (lonafarnib), a farnesyltransferase inhibitor approved to treat the rare and progressive genetic disease Hutchinson-Gilford progeria syndrome. Sentynl will pay up to $26 million for Zokinvy, with the final price subject to other adjustments including per diem reductions. Zokinvy is an oral small molecule drug that blocks the farnesyltransferase protein. It is also approved for use in processing-deficient progeroid laminopathies with specific genetic mutations. The companies expect to close the sale by April 24, 2024. As part of its bankruptcy filing, other bidders can also submit competing offers for Eiger’s assets through a court-supervised process. Eiger’s bankruptcy filing on Monday caps off a difficult year for the biotech. In September 2023, it announced that it was discontinuing the Phase III LIMT-2 study of its candidate peginterferon lambda for chronic hepatitis delta. A quarterly review by a Data Safety Monitoring Board (DSMB) found concerning safety signals associated with peginterferon lambda. Four patients who received the investigational therapy developed hepatobiliary events, which led to liver compensation, leading the DSMB to recommend the study’s discontinuation. In September 2022, the FDA also rejected Eiger’s application for an Emergency Use Authorization for peginterferon lambda, which the biotech was proposing for the treatment of mild-to-moderate COVID-19. Following this rejection, Eiger in June 2023 laid off 25% of its workers in a sweeping reprioritization and savings program. The initiative also included a pivot to its GLP-1 receptor antagonist avexitide, which at the time was being developed for post-bariatric hypoglycemia and congenital hyperinsulinism. Eiger expected the cost-cutting measures to support its operations through the fourth quarter of 2024. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

临床3期上市批准并购优先审批加速审批

2024-04-01

·BioSpace

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

Announces “Stalking Horse” Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas. The company also announced a “stalking horse” agreement for the sale of Zokinvy® (lonafarnib) to Sentynl Therapeutics, Inc., a biopharmaceutical company focused on rare diseases. Under the terms of the “stalking horse” agreement, subject to court approval, Sentynl Therapeutics will pay up to $26.0 million, subject to certain purchase price adjustments, including per diem reductions if the sale closes after April 24, 2024, for the acquisition of Zokinvy®. In accordance with Section 363 of the Bankruptcy Code, other potential bidders can submit competing bids for the company’s assets through a court-supervised process. Eiger filed customary “first day” motions with the court requesting relief designed to enable Eiger to transition into chapter 11 and uphold its commitments to stakeholders during the process without material disruption to its ordinary course of operations. The company intends to sell substantially all of its assets during the bankruptcy case and to facilitate an orderly wind down of its operations. Court filings and other information regarding the chapter 11 case are available via Kurtzman Carson Consultants LLC, a third-party bankruptcy claims and noticing agent, at: Inquiries regarding the case can be submitted via or by phone at (888) 733-1544 (U.S./Canada) or (310) 751-2638 (International). Eiger is represented by Sidley Austin LLP as its legal counsel, Alvarez & Marsal as its financial advisor and SSG Capital Advisors, LLC as its restructuring investment banker. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future financial condition; business strategy and plans and objectives for future operations; the sale of any or all of the company’s assets, including pursuant to the “stalking horse” agreement with Sentynl Therapeutics, Inc.; our ability to continue to supply Zokinvy® to patients; and our ability to maintain normal operations during the chapter 11 cases, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the potential negative impacts of the chapter 11 filings on our liquidity and results of operations; changes in our ability to meet our financial obligations during the chapter 11 process and to maintain contracts that are critical to our operations; the outcome and timing of the chapter 11 process and any potential asset sales; the effect of the chapter 11 filings and any potential asset sales on our relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the chapter 11 process or the potential asset sales; uncertainty regarding obtaining Bankruptcy Court approval of a sale of assets or other conditions to the potential asset sales; and the timing or amount of any distributions, if any, to Eiger’s stakeholders. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the “Risk Factors” section in Eiger’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Investors: Alexandra Santos Wheelhouse Life Science Advisors asantos@wheelhouselsa.com Media: Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com

并购

2024-03-26

·PRNewswire

The Progeria Research Foundation Selected as an Official Charity Partner in 2024 Boston Marathon

PRF's 10 Marathon Runners Raise Funds to cure Progeria, all connected to Sam Berns PEABODY, Mass., March 26, 2024 /PRNewswire/ -- The Progeria Research Foundation (PRF), the only nonprofit solely dedicated to finding treatments and the cure for Progeria, celebrates its first year as an Official Charity Partner of the Boston Athletic Association's 128th Bank of America Boston Marathon®. Represented by a team of 10 passionate runners, this partnership will bring vital funds for Progeria research endeavors, while casting a light on this ultra-rare disease and PRF's progress toward the cure. Continue Reading Progeria is an ultra-rare, fatal "rapid-aging" disease. Without treatment, children with Progeria die of heart disease at an average age of 14.5 years old. PRF is making extraordinary progress, including the discovery of one FDA-approved treatment, development of genetic and other drug therapies, and creation of healthcare guidelines - all of which are giving these special children longer, healthier lives while the work toward the cure diligently continues. All ten PRF runners are personally connected in some way to Sam Berns. Post this All ten PRF runners are personally connected in some way to Sam Berns, son of co-founders Drs. Leslie Gordon and Scott Berns and the inspiration behind the creation of PRF. "What is so amazing is that every runner has a connection to our son Sam, and that means the world to us," said Drs. Gordon and Berns. "From Foxboro neighbors, to middle school classmates, to athletes who got to know Sam at PRF's annual 5K Race for Research – it's heartwarming to know they're now representing The Progeria Research Foundation at the Boston Marathon, in Sam's honor." Sam Berns grew up in Foxboro, MA, and by his teenage years, he had inspired millions around the world with his resilience and positive attitude. In 2013, Sam starred in HBO's Emmy Award-winning documentary, "Life According to Sam," which features him realizing his dream of playing the snare drum in the Foxboro High School marching band. That same week, he delivered his iconic TEDx talk, "My Philosophy for a Happy Life," which is the 7th most viewed TED talk of all time and recently exceeded 100M views across the TED and TEDx platforms. Runner Paul Michienzie said, "I do this for the kids (and now young and thriving adults thanks to PRF) with Progeria and in memory and honor of Sam Berns, who was our Foxboro neighbor and close family friend. He inspires me every step of the way from the Hopkinton start to the finish line on Boylston Street, just near my office where Sam, his parents, Leslie and Scott, and our friends and families have watched other marathoners make their way to the finish line. When I cross that line again, I will be looking high and thinking of Sam!" "This is a tremendous honor to be invited to join the Bank of America's Official Charity Program in the 2024 Boston Marathon," said Audrey Gordon, President and Executive Director of The Progeria Research Foundation. "PRF's partnership with this prestigious organization will help us spotlight our mission to cure Progeria, while bringing in the necessary funds to propel our research endeavors to new heights." For more information on PRF's runners or to support their fundraising campaigns directly, click here. ABOUT THE PROGERIA RESEARCH FOUNDATION The Progeria Research Foundation (PRF) is a nonprofit organization established in 1999 by the family of Sam Berns, a child with Progeria. PRF funds and conducts research-related programs, including the clinical trials and studies that led to approval of the first-ever FDA-approved drug for Progeria, lonafarnib (Zokinvy®). PRF is the only organization in the world solely dedicated to finding treatments and the cure for Progeria and its aging related conditions, including heart disease. Due to the discovery of the biological connection between Progeria, heart disease and aging, finding the cure for one of the rarest diseases on earth could provide keys for treating millions of adults with heart disease and stroke associated with the natural aging process, as well as help the entire aging population. The organization fills a void, taking these children out of the background where they had been for more than 100 years and putting them and Progeria at the forefront of scientific efforts. For more information, and to support PRF's mission, please visit . SOURCE Progeria Research Foundation

100 项与洛那法尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04768	洛那法尼	A16AX	DB06448

研发状态

适应症	最高研发状态	国家/地区	公司
早衰	批准上市	列支敦士登更多	Eiger BioPharmaceuticals Europe Ltd. 更多
乳腺癌	终止	美国更多	Merck Sharp & Dohme Corp. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


LIFT HDV Study (EASL2020)	临床2期	丁型肝炎 HDV RNA \| HBV DNA	26	Peginterferon Lambda	鑰蓋積餘鹹顧醖獵願壓(淵築製淵窪繭構構觸壓) = 齋鹽鏇製觸鬱鏇簾艱衊積糧糧顧繭餘淵糧艱膚 (簾淵衊積鬱醖壓襯繭糧, 2.9–3.8)	-	2020-08-27
				Lonafarnib	鑰蓋積餘鹹顧醖獵願壓(淵築製淵窪繭構構觸壓) = 築膚顧鏇齋鬱廠鹽遞獵積糧糧顧繭餘淵糧艱膚 (簾淵衊積鬱醖壓襯繭糧, 2.9–4.5)
BRE07-126 (ASCO2011)	临床2期	局部晚期乳腺癌	29	Lonafarnib	(鬱簾鹽醖積壓製築築餘) = 構窪蓋醖繭鹽衊鑰選齋膚網獵鹽夢膚艱廠鹽鏇 (鏇積艱膚醖窪蓋膚醖鹽 )	不佳	2011-05-20
NCT03719313 (D-LIVR, EASL2021)	临床3期	慢性丁型肝炎	230	Lonafarnib	範觸窪膚積製衊餘衊製(網廠齋餘艱鹽艱廠網鏇) = 簾淵窪構顧襯繭觸艱齋積獵夢壓繭簾製鏇範糧 (襯鬱襯淵餘鹹鑰鹽鏇簾 )	-	2021-06-23
				Placebo	範觸窪膚積製衊餘衊製(網廠齋餘艱鹽艱廠網鏇) = 鑰齋壓築顧糧艱網餘願積獵夢壓繭簾製鏇範糧 (襯鬱襯淵餘鹹鑰鹽鏇簾 )
AGO-OVAR 15 (ASCO2014)	临床2期	卵巢癌一线	105	Lonafarnib + Carboplatin and Paclitaxel	(鏇築繭糧獵衊簾製衊膚) = 顧膚鹹構積鹽蓋淵淵窪範膚鏇蓋獵選窪壓繭鏇 (艱鑰壓獵壓願齋窪遞鹽 ) 更多	-	2014-05-20
				Placebo + Carboplatin and Paclitaxel	(鏇築繭糧獵衊簾製衊膚) = 選鏇顧構壓繭齋糧憲衊範膚鏇蓋獵選窪壓繭鏇 (艱鑰壓獵壓願齋窪遞鹽 ) 更多
ASCO2009	临床1期	胶质瘤	36	SCH 66336	(繭構願觸網衊網簾網蓋) = 鹽遞壓衊鬱願獵繭鹽觸遞餘網製繭憲蓋廠蓋窪 (積襯觸顧糧選範淵醖醖 )	-	2009-05-20
				Temozolomide (TMZ)	(繭構願觸網衊網簾網蓋) = 齋憲網範夢鏇淵獵構廠遞餘網製繭憲蓋廠蓋窪 (積襯觸顧糧選範淵醖醖 )
NCT00425607 (Pubmed \| Proc Natl Acad Sci U S A) 人工标引	临床2期	早衰	25	lonafarnib	(遞觸膚鏇膚夢範襯廠觸) = 衊獵鏇遞鏇構膚積鬱鑰齋醖衊餘獵顧鬱窪顧齋 (構獵糧糧鹹壓製衊衊餘 )	积极	2012-10-09
Pubmed \| Cancer Chemother Pharmacol	临床1期	晚期恶性实体瘤	-	Lonafarnib	(簾廠觸壓憲壓鬱鹹鏇餘) = 鏇鬱遞齋繭製簾夢鑰網鬱齋艱製窪醖觸製選醖 (鬱顧鹹壓淵廠顧繭鹽醖 )	-	2008-09-01
NCT00916747 \| NCT00879034 (Pubmed \| J Am Coll Cardiol) 人工标引	临床2期	早衰	37	pravastatin+zoledronic acid+lonafarnib	壓蓋窪鏇淵餘襯網齋願(鹽築糧蓋醖鬱窪選製積) = 遞壓積構窪壓網網襯艱襯夢餘蓋艱鑰夢繭襯築 (鏇選鹹餘構襯獵簾積艱 ) 更多	积极	2016-07-12
Pubmed	N/A	核纤层蛋白病 \| 早衰	-	Lonafarnib	築鹹願膚壓夢選壓壓積(鏇積範鏇鑰艱糧築鏇觸) = 淵淵繭衊廠鏇簾膚範繭憲構鬱網繭選夢夢壓範 (壓齋築艱鑰鑰獵憲遞醖 )	积极	2022-12-12
NCT01495585 (Pubmed \| Lancet Infect Dis) 人工标引	临床2期	丁型肝炎	14	lonafarnib (placebo-controlled 3:1)	糧鏇蓋壓鑰鹽齋壓網廠(願獵鬱夢憲襯蓋鏇醖製) = 襯構膚網獵淵鹽膚夢網艱鏇襯蓋築獵繭構艱獵 (鏇襯鏇築壓簾憲衊選衊 )	积极	2015-10-01
				lonafarnib (placebo-controlled 2:1)	糧鏇蓋壓鑰鹽齋壓網廠(願獵鬱夢憲襯蓋鏇醖製) = 遞壓餘鏇鏇獵鹽鹽觸餘艱鏇襯蓋築獵繭構艱獵 (鏇襯鏇築壓簾憲衊選衊 )